QS Investors’s Pacira BioSciences PCRX Stock Holding History

QS Investors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,851	Closed	-$709K	–	1234
2020 Q4	$709K	Hold	11,851	–	–	0.01%	620
2020 Q3	$713K	Sell	11,851 -54,762	-82%	-$3.18M	0.01%	564
2020 Q2	$3.5M	Sell	66,613 -5,500	-8%	-$230K	0.05%	301
2020 Q1	$2.42M	Buy	72,113 +3,900	+6%	+$162K	0.04%	352
2019 Q4	$3.11M	Sell	68,213 -1,000	-1%	-$42.5K	0.03%	433
2019 Q3	$2.63M	Hold	69,213	–	–	0.03%	464
2019 Q2	$3.01M	Buy	69,213 +3,250	+5%	+$138K	0.03%	434
2019 Q1	$2.51M	Buy	65,963 +65,812	+43,584%	+$2.57M	0.03%	507
2018 Q4	$7K	Buy	+151	New	+$7.05K	﹤0.01%	1548
2018 Q1	–	Sell	-3,300	Closed	-$151K	–	1982
2017 Q4	$151K	Hold	3,300	–	–	﹤0.01%	1298
2017 Q3	$124K	Hold	3,300	–	–	﹤0.01%	1373
2017 Q2	$157K	Buy	+3,300	New	+$153K	﹤0.01%	1300
2016 Q1	–	Sell	-4	Closed	-$1K	–	2043
2015 Q4	$1K	Buy	+4	New	+$226	﹤0.01%	1755

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

QS Investors's PCRX Position: Q1 2021 in Review

QS Investors sold out of Pacira BioSciences (PCRX) in Q1 2021, closing a stake of 11,851 shares — an estimated $709K sold.

QS Investors first reported a position in PCRX in Q4 2015 and held it in 13 quarters. The position peaked at $3.5M in Q2 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

QS Investors reported no remaining Pacira BioSciences position as of Q1 2021 after selling out during the quarter.
QS Investors sold 11,851 Pacira BioSciences shares in Q1 2021, an estimated $709K.
QS Investors first reported a position in Pacira BioSciences in Q4 2015 and held it in 13 quarters.
QS Investors's Pacira BioSciences position peaked at $3.5M in Q2 2020.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.